Abstract
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Especially in this disease, qualitative and quantitative aspects render the dysregulated epidermal growth factor receptor (HER1/EGFR) an outstanding therapeutic target. A variety of therapeutic compounds was developed to target HER1/EGFR among which the clinically most advanced agents are small molecule tyrosine kinase (TK) inhibitors. Unfortunately, clinical studies examining their therapeutic efficacy have so far failed to document a major therapeutic break-through in the setting of GBM. Thus, the targeted approach against HER1/EGFR likely requires a synergistic drug combination strategy to ultimately become successful in this disease. This patents review focuses on innovative therapeutic strategies combining HER1/EGFR-targeted TK inhibitors with novel agents which for the most part have not been evaluated for the treatment of GBM yet but which constitute interesting candidates for further evaluation in this setting.
Keywords: Erlotinib, high-grade glioma, Kit, pralatrexate, romidepsin, vascular disrupting agents, HER1/EGF, therapeutic target, drug combination strategy, TK inhibitors
Recent Patents on Anti-Cancer Drug Discovery
Title: Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Volume: 6 Issue: 3
Author(s): Georg Karpel-Massler, Christian R. Wirtz and Marc-Eric Halatsch
Affiliation:
Keywords: Erlotinib, high-grade glioma, Kit, pralatrexate, romidepsin, vascular disrupting agents, HER1/EGF, therapeutic target, drug combination strategy, TK inhibitors
Abstract: Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Especially in this disease, qualitative and quantitative aspects render the dysregulated epidermal growth factor receptor (HER1/EGFR) an outstanding therapeutic target. A variety of therapeutic compounds was developed to target HER1/EGFR among which the clinically most advanced agents are small molecule tyrosine kinase (TK) inhibitors. Unfortunately, clinical studies examining their therapeutic efficacy have so far failed to document a major therapeutic break-through in the setting of GBM. Thus, the targeted approach against HER1/EGFR likely requires a synergistic drug combination strategy to ultimately become successful in this disease. This patents review focuses on innovative therapeutic strategies combining HER1/EGFR-targeted TK inhibitors with novel agents which for the most part have not been evaluated for the treatment of GBM yet but which constitute interesting candidates for further evaluation in this setting.
Export Options
About this article
Cite this article as:
Karpel-Massler Georg, R. Wirtz Christian and Halatsch Marc-Eric, Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957748
DOI https://dx.doi.org/10.2174/157489211796957748 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Exploring the Nucleolar Proteome: Novel Concepts for Chaperone Trafficking and Function
Current Proteomics Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients
Current Pharmaceutical Design Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Multidrug Transporters as Drug Targets
Current Drug Targets The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Nanocarriers for Effective Brain Drug Delivery
Current Topics in Medicinal Chemistry Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease
Current Alzheimer Research Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging DNA-Based Methods to Prepare Helper Virus-Free Herpes Amplicon Vectors and Versatile Design of Amplicon Vector Plasmids
Current Gene Therapy A QSAR Study on Novel Series of Carbonic Anhydrase Inhibitors hCA IX—Tumor-Associated (Hypoxia)
Medicinal Chemistry The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry